Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New NRT gum

This article was originally published in The Tan Sheet

Executive Summary

Gum containing 2 mg nicotine tartrate salt, rather than nicotine polacrilex, yields "faster and better craving relief," researchers announce at Ninth Annual Meeting of the Society for Research on Nicotine & Tobacco. Raymond Niaura, PhD, Brown Medical School, et al., led a randomized, multi-center, open-label study in which 319 participants lit a cigarette of their choice without inhaling and then chewed either GlaxoSmithKline's Nicorette 2 mg or the experimental gum. After 30 minutes, "92% of rapid-release gum chewers had achieved meaningful relief of craving, compared to only 77% of those on Nicorette," researchers note. Study was sponsored by Bayer Consumer Care. JSR, a Maryland firm that develops "novel treatments for tobacco dependence," noted it is working with Biovail on commercialization of this product. NDA submission for new OTC drug is one to two years away, as Phase III placebo-controlled trials still need to be completed...

You may also be interested in...



Rapid Release Nicotine Gum Could Be Touted To Prevent Backsliding – Study

Rapid release nicotine gum may help smokers cope with cue-provoked or situation-induced cravings that may occur after quitting with traditional nicotine replacement therapy, according to a study published in the Sept. 9 online edition of Addiction

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 

Topics

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel